Saltar al contenido

Bonus Episode: Psychedelic Research Inside an Academic Medical Center with Scott Thompson, PhD

27 de octubre de 2026 · 1 h 12 min

Notas del episodio

In this bonus episode, Dr. Ben Everett speaks with Scott Thompson, PhD, professor of psychiatry at the University of Colorado School of Medicine, where he directs the Novel Therapeutics in the Brain and Behavior Innovation Center and leads the Psychedelic Public Policy Partnership. Drawing on more than 40 years of synaptic research, Dr. Thompson describes how an unexpected finding on SSRI action led his lab to show in mice that psilocybin's antidepressant-like effects persisted even when the 5-HT2A receptor was blocked, and what that finding means for the question of whether the psychedelic experience itself is the medicine.

As psychedelic compounds advance through late-stage development, clinicians face open questions about mechanism, trial design, safety, and access. This conversation covers functional unblinding and the search for objective endpoints such as anhedonia, what it takes to run Schedule I research inside an academic medical center, and real-world outcome and safety data from more than 2,300 people who received regulated psilocybin services in Colorado and Oregon. Dr. Thompson also discusses the role of psychotherapy, the evidence on microdosing, and phase III programs including Definium's DT120 LSD formulation and Beckley Atai's intranasal 5-MeO-DMT.

KEY EPISODE HIGHLIGHTS: A SUPERCHARGED SSRI [45:30]

“psychedelics do what SSRIs do. They just do it more potently and more quickly.”

Dr. Thompson's working hypothesis frames psychedelics as faster, stronger versions of a mechanism clinicians already use every day, which shapes how his lab tests whether the trip is required.

A DOSE CEILING IN REAL-WORLD DATA [27:31]

“people who got doses of psilocybin less than thirty milligrams displayed the same improvement in symptoms as people who got doses more than thirty-five”

Outcome data from more than 2,300 regulated psilocybin clients suggest a threshold rather than a linear dose-response, challenging the assumption that higher doses yield greater benefit.

MICRODOSING AND EXPECTANCY [31:00]

“There's strong evidence now that microdosing is primarily a placebo effect.”

Placebo-controlled studies show benefit tracks what participants believed they received rather than what they actually took, useful context when patients ask about microdosing.

CHAPTERS:

00:00 – Introduction: Is the Experience the Medicine?

02:00 – From Basel and Zurich to Psilocybin and Synaptic Plasticity

07:30 – Psychedelic Research and Policy at CU Anschutz

10:30 – Functional Unblinding and the Search for Objective Endpoints

15:00 – Facilitator Support, Placebo Response, and Predictive Biomarkers

20:00 – Building Safety Into Colorado's Regulated Psilocybin Services

24:30 – Real-World Outcomes From Colorado and Oregon Psilocybin Clients

28:00 – Dose Thresholds, MEQ-30 Scores, and the Evidence on Microdosing

32:00 – Running Schedule I Research: Regulation, Funding, and INDs

36:30 – Safety Signals: Psychosis, Suicidality, and Adverse Event Follow-Up

43:00 – Blocking the 5-HT2A Receptor: Is the Trip Necessary?

47:30 – Cost, Access, and Shorter-Acting Psychedelics

50:30 – Receptor Promiscuity and Non-Hallucinogenic Compounds

53:30 – The Role of Psychotherapy in Psychedelic Treatment

59:30 – Definium's DT120: Phase III Data, Payer Realities, and Dose Selection

01:07:00 – Beckley Atai's 5-MeO-DMT and Other Short-Acting Compounds

01:09:30 – Clinical Takeaways

LINKS:

Full transcript and show notes:

https://www.psychiatrist.com/jcp/ep27-psychedelic-research-academic-medical-center-scott-thompson/

Journal of Clinical Psychiatry

https://www.psychiatrist.com/jcp/

Publisher of peer-reviewed research discussed in this episode.

Dr. Scott Thompson – LinkedIn

https://www.linkedin.com/in/scott-thompson-241a1a15/

Harnessing Psilocybin (Hesselgrave et al., PNAS, 2021)

https://doi.org/10.1073/pnas.2022489118

Dr. Thompson's mouse study showing psilocybin's antidepressant-like effects persisted despite 5-HT2A receptor blockade.

Colorado Natural Medicine Program

https://dpo.colorado.gov/NaturalMedicine

State program for regulated psilocybin services discussed in this episode.

Definium Therapeutics

https://definiumtx.com

Developer of DT120, the LSD formulation with phase III results in MDD and GAD.

#Psilocybin #PsychedelicMedicine #LSD #Neuroplasticity #FunctionalUnblinding

Todos los episodios de The Journal of Clinical Psychiatry Podcast

Ajustes

Visualización

Idioma

Determina qué emisoras ves primero en la página de inicio.

Historial

Las emisoras y episodios escuchados recientemente y tus últimas búsquedas solo se guardan en este navegador.

Avisos

Un breve aviso cuando un pódcast que sigues tiene un episodio nuevo. Puedes desactivar pódcast concretos con la campana de su página.

Cuenta

Guarda tus favoritos: en la app y en la web.

Atajos de teclado

/
Abrir búsqueda
Espacio
Reproducir o pausar
← →
En el reproductor: 15 s atrás, 30 s adelante (episodios) · en una fila: siguiente tarjeta
↑ ↓
En una fila: destino dentro de la tarjeta
Inicio / Fin
En una fila: primera o última tarjeta
Esc
Cerrar ventana o menú
?
Este resumen
Reproduciendo ahora

Ir a la emisora

A continuación

    Añade episodios con «A continuación»: sonarán después del episodio actual.